Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMTKSVO)

Drug Name
T0070907 Drug Info
Synonyms
2-Chloro-5-nitro-N-4-pyridinylbenzamide; 313516-66-4; 2-CHLORO-5-NITRO-N-4-PYRIDINYLBENZAMIDE; 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide; T 0070907; T-0070907; 2-chloro-5-nitro-N-pyridin-4-ylbenzamide; 2-Chloro-5-nitro-N-(4-pyridyl)benzamide; CHEMBL510698; Benzamide, 2-chloro-5-nitro-N-4-pyridinyl-; 2-chloro-5-nitro-n-4-pyridinyl-benzamide; SR-01000392700; AC1MCROG; Oprea1_586106; ZINC3381; GTPL3444; SCHEMBL2128178; CTK6H1028; KS-00000MYU; CHEBI:92553; DTXSID30380504; MolPort-001-763-336; FRPJSHKMZHWJBE-UHFFFAOYSA-N; HMS3268J16; HMS3651P21; HMS3262J21; T 0070907
Cross-matching ID
PubChem CID
2777391
ChEBI ID
CHEMBL510698
CAS Number
CAS 313516-66-4
TTD Drug ID
D03BPG

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Ferroptosis 2.20 0.00e+0 36/41 (87.8%) HMOX1;STEAP3;CP;...
Glycosphingolipid biosynthesis 1.96 1.18e-2 37/57 (64.91%) HEXB;ST3GAL5;B4GALT4;...
Cysteine and methionine metabolism 1.89 1.31e-2 43/50 (86%) GCLM;CBS;PSAT1;...
Selenocompound metabolism 1.79 2.36e-2 11/17 (64.71%) TXNRD1;SEPHS1;CTH;...
Protein export 1.79 2.20e-2 17/23 (73.91%) HSPA5;SEC61G;SRPRB;...
Various types of N-glycan biosynthesis 1.72 3.40e-2 26/39 (66.67%) FUT8;HEXB;MAN1C1;...
Protein processing in endoplasmic reticulum 1.72 3.36e-2 127/171 (74.27%) HERPUD1;HSPA6;HSPA5;...
Thiamine metabolism 1.72 2.94e-2 12/15 (80%) ALPL;TPK1;AK2;...
Other glycan degradation 1.68 3.75e-2 13/18 (72.22%) HEXB;MAN2B1;NEU1;...
Regulation of lipolysis in adipocytes -1.82 4.09e-2 52/55 (94.55%) GNAI1;AKT1;PTGER3;...
Primary immunodeficiency -1.83 3.90e-2 33/38 (86.84%) CD8B;RAG1;PTPRC;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H